JP2021502807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502807A5 JP2021502807A5 JP2020524049A JP2020524049A JP2021502807A5 JP 2021502807 A5 JP2021502807 A5 JP 2021502807A5 JP 2020524049 A JP2020524049 A JP 2020524049A JP 2020524049 A JP2020524049 A JP 2020524049A JP 2021502807 A5 JP2021502807 A5 JP 2021502807A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- subunit
- trimer
- sequence
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023132911A JP2023156458A (ja) | 2017-11-01 | 2023-08-17 | 新規足場ｈｉｖ－１ワクチン免疫原 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580038P | 2017-11-01 | 2017-11-01 | |
| US62/580,038 | 2017-11-01 | ||
| PCT/US2018/058540 WO2019089817A1 (en) | 2017-11-01 | 2018-10-31 | Novel scaffolded hiv-1 vaccine immunogens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132911A Division JP2023156458A (ja) | 2017-11-01 | 2023-08-17 | 新規足場ｈｉｖ－１ワクチン免疫原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502807A JP2021502807A (ja) | 2021-02-04 |
| JP2021502807A5 true JP2021502807A5 (enExample) | 2021-12-09 |
| JP7730640B2 JP7730640B2 (ja) | 2025-08-28 |
Family
ID=66245896
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524049A Active JP7730640B2 (ja) | 2017-11-01 | 2018-10-31 | 新規足場ｈｉｖ－１ワクチン免疫原 |
| JP2023132911A Pending JP2023156458A (ja) | 2017-11-01 | 2023-08-17 | 新規足場ｈｉｖ－１ワクチン免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132911A Pending JP2023156458A (ja) | 2017-11-01 | 2023-08-17 | 新規足場ｈｉｖ－１ワクチン免疫原 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10780178B2 (enExample) |
| EP (1) | EP3704137A4 (enExample) |
| JP (2) | JP7730640B2 (enExample) |
| CN (1) | CN111542534B (enExample) |
| AU (1) | AU2018358238B2 (enExample) |
| CA (1) | CA3081331A1 (enExample) |
| IL (1) | IL274130B2 (enExample) |
| WO (1) | WO2019089817A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3704137A4 (en) * | 2017-11-01 | 2021-08-11 | The Scripps Research Institute | NEW SCAFFOLD-TYPE ANTI-HIV-1 IMMUNOGENS |
| WO2019241483A1 (en) | 2018-06-13 | 2019-12-19 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
| WO2020061564A1 (en) * | 2018-09-23 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use |
| US10906944B2 (en) | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
| US20230181718A1 (en) * | 2021-12-14 | 2023-06-15 | The Scripps Research Institute | Methods and compositions related to viral vaccines with improved properties |
| JP2025539418A (ja) * | 2022-11-29 | 2025-12-05 | ザ スクリプス リサーチ インスティテュート | 新規ナノ粒子足場を含有するワクチン |
| WO2024241233A1 (en) * | 2023-05-25 | 2024-11-28 | Zydus Lifesciences Limited | Protein based chimeric vaccine for dyslipidemia & atherosclerosis |
| CN116874600B (zh) * | 2023-07-13 | 2024-07-05 | 浙江大学 | 来自纳米抗体可靶向cd163受体的短肽的制备方法及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US4965343A (en) | 1988-01-28 | 1990-10-23 | Hoffmann-La Roche Inc. | Method of peptide synthesis |
| EP0735893B1 (en) | 1993-09-14 | 2008-11-26 | Pharmexa Inc. | Pan dr-binding peptides for enhancement of the immune response |
| US5849954A (en) | 1996-01-18 | 1998-12-15 | Research Corporation Technologies, Inc. | Method of peptide synthesis |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| AU2003296330A1 (en) * | 2002-12-10 | 2004-06-30 | Epimmune Inc. | Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions |
| RU2540871C2 (ru) * | 2008-02-01 | 2015-02-10 | Альфа-О Пептидес Аг | Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин |
| AU2013305848B2 (en) * | 2012-08-21 | 2020-10-15 | Institute For Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, Tau, and alpha-synuclein |
| EP2765138B1 (en) | 2012-11-05 | 2018-01-10 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
| CN105263506B (zh) * | 2013-01-07 | 2018-03-09 | 贝丝以色列女执事医疗中心 | 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法 |
| US10400015B2 (en) * | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| US10501733B2 (en) * | 2015-02-27 | 2019-12-10 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| WO2016205704A2 (en) | 2015-06-17 | 2016-12-22 | International Aids Vaccine Initiative | Engineered outer domain (eod) of hiv gp120, mutants and use thereof |
| WO2017152146A2 (en) | 2016-03-03 | 2017-09-08 | Duke University | Compositions and methods for inducing hiv-1 antibodies |
| EP3704137A4 (en) * | 2017-11-01 | 2021-08-11 | The Scripps Research Institute | NEW SCAFFOLD-TYPE ANTI-HIV-1 IMMUNOGENS |
| WO2019241483A1 (en) * | 2018-06-13 | 2019-12-19 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
-
2018
- 2018-10-31 EP EP18872837.2A patent/EP3704137A4/en active Pending
- 2018-10-31 CN CN201880071629.1A patent/CN111542534B/zh active Active
- 2018-10-31 US US16/177,165 patent/US10780178B2/en active Active
- 2018-10-31 AU AU2018358238A patent/AU2018358238B2/en active Active
- 2018-10-31 WO PCT/US2018/058540 patent/WO2019089817A1/en not_active Ceased
- 2018-10-31 JP JP2020524049A patent/JP7730640B2/ja active Active
- 2018-10-31 IL IL274130A patent/IL274130B2/en unknown
- 2018-10-31 CA CA3081331A patent/CA3081331A1/en active Pending
-
2020
- 2020-09-15 US US17/021,821 patent/US11452771B2/en active Active
-
2022
- 2022-08-26 US US17/896,799 patent/US20230190910A1/en not_active Abandoned
-
2023
- 2023-08-17 JP JP2023132911A patent/JP2023156458A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502807A5 (enExample) | ||
| IL274130B1 (en) | HIV–1 vaccine immunogens with novel scaffolds | |
| CN107434827B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| JP2015509707A5 (enExample) | ||
| JP2018510215A5 (enExample) | ||
| JP2016199557A5 (enExample) | ||
| JP2017519491A5 (enExample) | ||
| Hastie et al. | Lassa virus glycoprotein: stopping a moving target | |
| JP2020519298A5 (enExample) | ||
| JP2019536440A5 (enExample) | ||
| JP2018510639A (ja) | キメラ抗原受容体 | |
| JP2019521643A5 (enExample) | ||
| JP2019535268A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2012530761A5 (enExample) | ||
| JPWO2019241483A5 (enExample) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2020517635A5 (enExample) | ||
| JP2019522466A5 (enExample) | ||
| JP2019514361A5 (enExample) | ||
| JP2019522626A5 (enExample) | ||
| JP2018509936A5 (enExample) | ||
| JP2019501647A5 (enExample) | ||
| JP2019530441A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| IL278418B2 (en) | Vaccine composition |